Understanding Non-Hodgkin's Lymphoma Prognosis
Non-Hodgkin's lymphoma encompasses many subtypes of lymphoma, or cancer originating in the lymphatic system. Survival rates and prognosis for non-Hodgkin's lymphoma can vary significantly depending on factors like subtype, stage at diagnosis, age, and overall health.
Non-Hodgkin's Lymphoma Subtypes
There are over 60 subtypes of non-Hodgkin's lymphoma. Some common subtypes include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Burkitt lymphoma
- Lymphoblastic lymphoma
Survival outlook can differ greatly amongst subtypes. For example, DLBCL and follicular lymphoma generally have better prognosis than mantle cell or lymphoblastic lymphoma.
Staging of Non-Hodgkin's Lymphoma
In addition to subtype, doctors determine the stage of non-Hodgkin's lymphoma when diagnosing. Higher stages indicate more advanced disease.
- Stage I: Single lymph node region or single organ affected
- Stage II: Two or more lymph node regions affected on same side
- Stage III: Lymph node regions affected on both sides
- Stage IV: Widespread organ involvement
Typically, earlier stage I and II lymphomas have better prognosis than later stage III and IV.
Non-Hodgkin's Lymphoma Survival Rates by Age
Both subtype and stage significantly impact survival statistics. But age at diagnosis also plays a role. Younger non-Hodgkin's lymphoma patients typically have better outcomes.
Survival Rates for Young Adults
Non-Hodgkin's lymphoma is one of the most common cancers in the 15-24 age demographic. Overall 5-year relative survival rates for adolescents and young adults include:
- Ages 15-19: 83%
- Ages 20-29: 80%
- Ages 30-39: 78%
The most common subtypes seen in young people like Burkitt lymphoma and lymphoblastic lymphoma respond better to high-intensity chemotherapy.
Survival Rates for Older Adults
In general, non-Hodgkin's lymphoma survival rates decline with older age. However, prognosis varies significantly by subtype and stage of disease.
For example, localized stage I and II follicular lymphomas have over 90% 5-year survival rates for all older age groups. However, more aggressive stage IV diffuse large B-cell lymphoma drops from 71% 5-year survival at ages 60-69 down to 53% at age 80+.
Factors Affecting Non-Hodgkin’s Lymphoma Prognosis
While subtype, staging, and age play a major role, other factors impact an individual's prognosis following a non-Hodgkin's lymphoma diagnosis.
General Health
Those diagnosed with non-Hodgkin's lymphoma who are otherwise in good health tend to have better outcomes. Not having other chronic conditions allows patients to undergo more aggressive treatments.
Performance Status
ECOG performance status assesses a cancer patient's daily living abilities on a scale of 0-5. People with scores of 0-1 indicating higher functioning have higher lymphoma survival rates than those with poorer performance scores.
Chromosomal Abnormalities
Certain lymphoma cells contain genetic mutations and extra or missing chromosomes. Some chromosomal abnormalities cause faster growing, more aggressive lymphomas which negatively impact prognosis.
Blood Lactate Dehydrogenase Levels
High blood LDH levels are associated with fast growing lymphomas and more advanced disease. Elevated LDH levels indicate lower survival outlooks.
Cancer Cells in Bone Marrow
Finding lymphoma cells in the bone marrow signifies the disease has already begun spreading to other organs and adversely affects non-Hodgkin’s lymphoma life expectancy.
Response to Treatment
Patients whose lymphoma immediately responds positively to first-line treatments with chemotherapy, radiation, immunotherapy or stem cell transplants typically have the most favorable prognoses.
Improving Survival Rates for Non-Hodgkin's Lymphoma
Researchers continue working to develop more effective first-line treatments as well as better second-line therapies for relapsed and treatment-resistant non-Hodgkin’s lymphomas to further improve prognosis and long-term survival over the coming decades.
Targeted Therapies
Cancer drugs that specifically target genetic mutations or proteins found in lymphoma cells help avoid harming healthy cells. These include:
- BCL-2 inhibitors like venetoclax
- BTK inhibitors like ibrutinib
- PI3K inhibitors like copanlisib and duvelisib
CAR T-Cell Therapy
CAR T-cell therapy genetically engineers a patient’s own immune T-cells to recognize and attack lymphoma cells. Approvals keep expanding for use against certain non-Hodgkin's lymphomas.
Immunotherapy Combinations
Combining immunotherapy agents like lenalidomide, rituximab, obinutuzumab and polatuzumab with chemotherapy improves outcomes for many lymphoma subtypes and stages.
Testing for Chromosomal and Genetic Mutations
Testing lymphoma cells for specific mutations helps oncologists select the best personalized treatment plan for each patient to improve response rates.
Coping with a Non-Hodgkin’s Lymphoma Diagnosis
Being diagnosed with non-Hodgkin’s lymphoma understandably induces fear and anxiety regarding prognosis and life expectancy. While statistics provide general outlooks, actual outcomes vary person to person based on unique disease attributes and response to modern therapies.
Seeking Social Support
Get emotional support by confiding in close friends and family, joining a cancer support group, or seeing a therapist or counselor. Connecting with others facing similar challenges can help you feel less alone.
Communicating with Your Medical Team
Have open discussions with your oncologists, nurses and other care providers about your specific subtype and prognosis as well as treatment options. Ask any questions you have about outlook or clinical trial opportunities.
Exploring Complementary Therapies
Some patients find outlets like meditation, yoga, massage, acupuncture and nature soothing while undergoing traditional lymphoma treatments. Communicate with your care team before adding any complementary modalities.
Making Lifestyle Changes
Focus on getting enough sleep, eating a balanced nutritious diet, exercising when possible, and finding relaxing activities like reading or puzzles that help distract from constant cancer worries.
Joining a Support Community
Online lymphoma support groups through resources like the Leukemia & Lymphoma Society and Lymphoma Research Foundation connect you with fellow patients for sharing stories and exchanging encouragement.
FAQs
How does age impact non-Hodgkin’s lymphoma prognosis?
Younger non-Hodgkin's lymphoma patients generally have better survival outlooks, with 5-year relative survival rates over 80% for those under age 40. Survival rates decline with older age depending greatly on subtype and stage at diagnosis.
What are the most common non-Hodgkin's lymphoma subtypes in young adults?
The most common subtypes of lymphoma seen in young people are Burkitt lymphoma and lymphoblastic lymphoma. These tend to respond better to high-intensity chemotherapy in younger healthier patients.
What factors besides age affect prognosis with non-Hodgkin’s lymphoma?
Other prognosis factors include subtype, stage at diagnosis, overall health status, performance ability, specific chromosomal abnormalities, blood LDH levels, cancer spread to bone marrow, and response to initial treatments.
How is research improving future outlooks for non-Hodgkin’s lymphoma patients?
New therapies being developed including targeted agents, CAR T-cell therapy, immunotherapy combinations, and testing for genetic mutations to enable personalized treatment plans to improve survival over time.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Add Comment